Neurotech Pharmaceuticals   Report issue

For profit Phase 2
Founded: Lincoln RI United States (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2007
NCT00447980
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Neurotech Pharmaceuticals | Neurotech Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

aflibercept (zaltrap) (1 trial)

ciliary neurotrophic factor (8 trials)

nt-503-3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 2)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Syndrome (Phase 2)

Telangiectasis (Phase 2)

Usher Syndromes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 3